Treat All Known Disease

This patient (1) presents with oligometastatic, Gleason 5 + 4 adenocarcinoma, with a presenting prostate-specific antigen level of 80 μg/L. On the basis of the biopsy extension into periprostatic fat, he has T3a disease. He has been treated initially with androgen deprivation therapy and docetaxel. On the basis of the STAMPEDE data, he can expect a median response duration of 3 years and survival of 6 years (2). He may, however, not achieve this having a high-grade tumor, which predicts for a shorter response to androgen deprivation therapy.

http://ift.tt/2qAzhLG